Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib in Japanese Patients With Relapsed/Refractory Multiple Myeloma
NCT04272775Phase 1Terminated
- Sponsor
- Takeda
- Start
- Jun 2012
- Primary completion
- Feb 2019
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of ixazomib in multiple myeloma (MM) (4 arms), sponsored by Takeda. Primary endpoints: Dose Limiting Toxicities, Treatment-emergent Adverse Events and 2 more. Started Jun 2012; status: terminated.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04272775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04272775.